Search global stocks & ETFs...Ctrl K

Learn Mode

RXRX - Recursion Pharmaceuticals Inc

73

$2.93

-$0.11 (-3.618%)

At market close

$2.93

-$0.005 (-0.171%)

After Hours 5/15/26, 11:59 PM

Score

2.78/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

RXRX

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$1.56B

Industry

Biotechnology

EPS (TTM)

-$1.05

P/E (TTM)

0.00

Div & Yield

FCF Payout Ratio

P/S (TTM)

23.42

P/B

1.52

Diluted Shares

529.30M

Ex-Dividend

Next Earnings

08-03

Forward P/E

0.00

Payout Ratio

P/FCF (TTM)

0.00

FCF Yield

Earnings Yield

-36.00%

52 Week Range

Score Card

Explore Scores Tab

2.78

Average

Recursion Pharmaceuticals Inc has a current cash runway of 24.10 months. The cash runway is the amount of time the business has at its current burn rate before it will need to take on debt or dilute shareholders to raise more money. However, it has grown revenue at 11.07% over the past year, which is strong growth.

Valuation Model

Key Score

1.00

Very Bad

Management

2.00

Bad

Growth

1.00

Very Bad

Profitability

4.00

Good

Fin. Health

4.00

Good

Dividends

Analyst

4.00

Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form SCHEDULE 13G

Unknown Form Type

Filed on 2026-05-12 11:53:03

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-08 16:59:21

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-07 16:44:43

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-07 11:13:53

Form 10-Q

General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-05-06 06:32:40

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-06 06:31:39

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-05 10:22:27

Form ARS

Unknown Form Type

Filed on 2026-04-30 16:35:08

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-04-30 16:34:28

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-04-30 16:33:45

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-30 16:31:24

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-24 16:23:14

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$11.55

294.2%

Avg:

$6.85

133.7%

Low:

$3.03

3.4%

(% change is relative to the current stock price: $2.93)

Analyst Recommendations

Go to Analyst Tab

3.71

Good

14%

Strong Buy (2)

43%

Buy (6)

43%

Hold (6)

Sell (0)

Strong Sell (0)

About

Website
https://www.recursion.com/
Address
41S Rio Grande Street, Salt Lake City UTAH, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1601830

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah and currently employs 600 full-time employees. The company went IPO on 2021-04-16. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The firm integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

IPO Date

2021-04-16

Industry

Biotechnology

Total Employees

600

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

RXRX - Recursion Pharmaceuticals Inc

73

$2.93

-$0.11 (-3.618%)

$2.93

-$0.005 (-0.171%)

2.78/5

Stock Unlock

Stock Profile

Score Card

Average

Insider Transactions

Market News

Form SCHEDULE 13G

Filed on 2026-05-12 11:53:03

Form 4

Filed on 2026-05-08 16:59:21

Form 4

Filed on 2026-05-07 16:44:43

Form 144

Filed on 2026-05-07 11:13:53

Form 10-Q

Filed on 2026-05-06 06:32:40

Form 8-K

Filed on 2026-05-06 06:31:39

Form 144

Filed on 2026-05-05 10:22:27

Form ARS

Filed on 2026-04-30 16:35:08

Form DEFA14A

Filed on 2026-04-30 16:34:28

Form DEF 14A

Filed on 2026-04-30 16:33:45

Form 8-K

Filed on 2026-04-30 16:31:24

Form 4

Filed on 2026-04-24 16:23:14

Financials

Price Targets

294.2%

133.7%

3.4%

Analyst Recommendations

About

Similar Stocks